Article
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Blood - 29 Dec 2016
Xu-Monette Zijun Y, Li Ling, Byrd John C, Jabbar Kausar J, Manyam Ganiraju C, Maria de Winde Charlotte, van den Brand Michiel, Tzankov Alexandar, Visco Carlo, Wang Jing, Dybkaer Karen, Chiu April, Orazi Attilio, Zu Youli, Bhagat Govind, Richards Kristy L, Hsi Eric D, Choi William W L, Huh Jooryung, Ponzoni Maurilio, Ferreri Andrés J M, Møller Michael B, Parsons Ben M, Winter Jane N, Wang Michael, Hagemeister Frederick B, Piris Miguel A, Han van Krieken J, Medeiros L Jeffrey, Li Yong, van Spriel Annemiek B, Young Ken H
Abstract excerpt
CD37 (tetraspanin TSPAN26) is a B-cell surface antigen widely expressed on mature B cells. CD37 is involved in immune regulation and tumor suppression but its function has not been fully elucidated. We assessed CD37 expression in de novo diffuse large B-cell lymphoma (DLBCL), and investigated its clinical and biologic significance in 773 patients treated with rituximab plus cyclophosphamide, doxorubicin,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.